Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

[1]  J. Schellens,et al.  Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity , 2017, British Journal of Cancer.

[2]  R. Danesi,et al.  Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. , 2017, Current pharmaceutical design.

[3]  J. Schellens,et al.  Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? , 2016, Cancer treatment reviews.

[4]  S. Barni,et al.  Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Schellens,et al.  Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Oyen,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. López-Fernández,et al.  Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. , 2016, Pharmacogenomics.

[8]  R. Greil,et al.  DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. , 2016, JAMA oncology.

[9]  Tarjinder Sahota,et al.  Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. , 2016, Mutagenesis.

[10]  R. Diasio,et al.  Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial. , 2016, JAMA oncology.

[11]  P. Novotny,et al.  Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. , 2016, The Lancet. Oncology.

[12]  A. V. van Kuilenburg,et al.  Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. , 2016, British journal of clinical pharmacology.

[13]  D. Sargent,et al.  Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). , 2016, Pharmacogenetics and genomics.

[14]  J. Sanderson,et al.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[15]  M. Simmaco,et al.  Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction , 2015, The Pharmacogenomics Journal.

[16]  D. Sargent,et al.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). , 2014, Journal of the National Cancer Institute.

[17]  S. Barni,et al.  Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients , 2014, Scientific Reports.

[18]  J. Maring,et al.  Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency , 2014, The Pharmacogenomics Journal.

[19]  U. Amstutz,et al.  Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity , 2014, International journal of cancer.

[20]  D. Kerr,et al.  Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing , 2013, Clinical pharmacology and therapeutics.

[22]  L. Teh,et al.  Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer Patients , 2013, Therapeutic drug monitoring.

[23]  S. Tishkoff,et al.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent , 2013, The Pharmacogenomics Journal.

[24]  C. Punt,et al.  Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer , 2011, Clinical Cancer Research.

[25]  L. Zoetekouw,et al.  Dihydropyrimidine Dehydrogenase Deficiency Caused by a Novel Genomic Deletion c.505_513del of DPYD , 2010, Nucleosides, nucleotides & nucleic acids.

[26]  C. Eng.  Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer , 2009, Nature Reviews Clinical Oncology.

[27]  A. Meindl,et al.  Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients , 2008, PloS one.

[28]  E. Gamelin,et al.  5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. , 2007, Cancer letters.

[29]  X. Solé,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[30]  L. Kruglyak,et al.  Patterns of linkage disequilibrium in the human genome , 2002, Nature Reviews Genetics.

[31]  Martin R. Johnson,et al.  A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. , 2002, Pharmacogenetics.

[32]  A. B. Kuilenburg,et al.  Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients , 1999, British Journal of Cancer.

[33]  J. Novotný,et al.  Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. , 2009, Neoplasma.